Expanded cord blood shows potential for use in adult bone marrow transplants

December 4, 2018, Duke University Medical Center

Umbilical cord blood stem cells that are cultured and expanded outside the body before being used for bone marrow transplant in adult blood cancer patients appear safe and restore blood count recovery faster than standard cord blood.

The findings, led by a Duke Cancer Institute researcher, are from a phase I/II study of the biologic treatment, NiCord, at 11 clinical trial sites. The study is publishing online Dec. 4 in the Journal of Clinical Oncology and advances efforts to improve cord blood use among adults who have been diagnosed with blood cancers.

Cord blood has been shown to be a rich source of stem cells and is commonly used for transplantation in children, but the number of stem cells tends to be too low for adults, discouraging their use. In the expansion process of the investigational therapy, umbilical cord blood undergoes a three-week cultivation of the stem cells outside the patient before transplantation.

"Although umbilical cord blood transplantation has been used for 30 years, expansion technology represents an opportunity to improve the results for ," said Mitchell Horwitz, M.D., professor of medicine at Duke and lead author of the study.

"This study shows that a single unit of this product appears to be delivered safely to patients around the world."

A larger, phase III trial of NiCord is already underway and if results are replicated, the product's manufacturer, Gamida Cell, plans to seek FDA approval of NiCord, Horwitz said. The company provided funding support for the clinical trials.

In their study, Horwitz and colleagues analyzed results for 36 adult patients with blood cancers who received a cord blood transplant with NiCord. This group was compared to a historic group of closely matched patients listed in the Center for International Blood and Marrow Transplant Research databank who received cord blood without expansion.

The researchers reported that 94 percent of patients who received the investigational product had successful engraftment within six weeks. Two patients experienced secondary graft failure attributable to viral infections.

Blood count recovery occurred much earlier among the patients who received the investigational product—an important milestone that improves a patient's ability to fight infections. The median time to neutrophil recovery was 11.5 days for patients receiving the NiCord, compared to 21 days for those receiving cord blood alone. Platelet recovery was 34 days for the NiCord group versus 46 days for cord blood alone.

"Compared to standard cord blood transplant, the reduction in translates into significant improvement in the safety profile of the transplant procedure," Horwitz said. "It's when their counts are low that are most vulnerable to infections, so by reducing that time to 11.5 days, we shorten that vulnerable period."

Explore further: Treating leukemia with cord-blood transplant looks promising

Related Stories

Treating leukemia with cord-blood transplant looks promising

September 8, 2016
(HealthDay)—Umbilical cord blood may work as well as current alternatives for adults and children with leukemia—or even better in some cases, according to a study published in the Sept. 8 issue of the New England Journal ...

Discovery improves use of umbilical cord blood as cancer therapy

January 5, 2017
A clinician/scientist, who studies ways to make cord-blood transplants for leukemia and lymphoma patients safer and more effective, recently reported a new finding in the journal Blood. An accompanying editorial called the ...

Researchers say therapy improves stem cell engraftment in umbilical cord blood transplant recipients

December 12, 2011
A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases, a phase I clinical trial led by ...

Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells

December 9, 2013
Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers.

Cord blood outperforms matched, unrelated donor in bone marrow transplant

July 26, 2016
A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009-2014, finding that three years post transplant, the incidence of severe chronic graft-versus-host ...

Pre-transplant umbilical cord blood expansion speeds establishment of new blood supply in patients

December 12, 2012
Donated umbilical cord blood establishes a new blood supply in patients more quickly after transplantation when it is first expanded in the lab on a bed of cells that mimics conditions in the bone marrow, researchers report ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Breast cancer drug could create chink in the armour of pancreatic cancer

December 11, 2018
The well-known drug tamoxifen could exploit a weakness in the physical 'scaffolds' around tumours, according to research led by Imperial.

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.